Last reviewed · How we verify
NCT06080490
Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
trial testing TAC C/D ratio in Graft Vs Host Disease in 125 participants. Completed in 31 December 2024.
29 September 2024
Quick facts
| Lead sponsor | University of Pisa |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 125 |
| Start date | 29 September 2023 |
| Primary completion | 29 September 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- TAC C/D ratio — full drug profile →
Conditions studied
- Graft Vs Host Disease — all drugs for Graft Vs Host Disease →
- Transplant Failure — all drugs for Transplant Failure →
- Stem Cell Transplant Complications — all drugs for Stem Cell Transplant Complications →
Sponsor
University of Pisa
Who can join
Adults 1 Month to 18, any sex, with Graft Vs Host Disease or Transplant Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this retrospective observational study is to investigate any possible association among tacrolimus (TAC) blood concentrations, clinical efficacy and tolerability. Therefore, the main questions it aims to answer are: 1. to clarify which variables, how and to what extent influence daily TAC blood concentrations in pediatric allo-hematopoietic stem cell transplantation (HSCT) recipients; 2. to investigate the incidence of graft-versus-host disease (GVHD) and graft failure according to TAC exposure. Pediatric patients administered TAC to prevent GVHD after an allogeneic bone marrow transplantation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06080490
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Graft Vs Host Disease
Currently open trials in the same condition.
- NCT07006506 — A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant · Phase 2 · recruiting
- NCT06008808 — Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release S · Phase 1 · recruiting
- NCT07365696 — Fatigue and Cognitive Dysfunction Due to Synaptopathy or Graft Versus Host (GVH) Disease in the Brain. · recruiting
- NCT05621759 — Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD · Phase 2 · active not recruiting
- NCT05236062 — Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial · NA · recruiting
Other University of Pisa trials
Trials by the same sponsor.
- NCT07520890 — Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs) · recruiting
- NCT07444229 — Team-Based Learning Integrated Into Clinical Simulation in Nursing Students · NA · not yet recruiting
- NCT07041983 — 24-h Energy Expenditure and Anti-obesity Medication · enrolling by invitation
- NCT07510685 — Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial) · NA · completed
- NCT07055152 — Retinal OCTA for Microvascular Dysfunction Evaluation and Outcome Prediction in MINOCA Patients · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06080490 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pisa
- Last refreshed: 5 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06080490.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing